Daiichi Sankyo Shares Jump on Multibillion-Dollar Drug Development Deal With Merck
By Kosaku Narioka
Daiichi Sankyo shares rose sharply after the Japanese drugmaker announced a multibillion dollar deal with Merck to jointly develop and commercialize three cancer drug candidates.
The shares were recently 12% higher at 4,021 yen after rising as much as 18% earlier.
Daiichi Sankyo said Friday that it would receive $4 billion upfront from the U.S. drugmaker and $1.5 billion additionally over the next two years as part of the agreement. The Japanese company could also receive up to $16.5 billion if future sales milestones are achieved.
The Japanese and U.S. drugmakers will jointly develop and potentially commercialize three of Daiichi Sankyo's lung and ovarian drug candidates worldwide, except in Japan where Daiichi Sankyo will maintain exclusive rights, they said.
The three drug candidates -- patritumab deruxtecan, ifinatamab deruxtecan and raludotatug deruxtecan -- are in various stages of clinical development.
Daiichi Sankyo said it would announce the impact of the Merck deal on its earnings at an appropriate time in the future.
For the fiscal year ending March 2024, the Japanese drugmaker had projected revenue would increase 13% to 1.450 trillion yen ($9.68 billion) and net profit to climb 5.3% to Y115.00 billion. The company is scheduled to announce its first-half results on Oct. 31.
Write to Kosaku Narioka at kosaku.narioka@wsj.com
(END) Dow Jones Newswires
October 19, 2023 22:23 ET (02:23 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
What History Tells Us About the Fed’s Next Move
-
What’s Happening In the Markets This Week
-
Alphabet’s New Dividend: What Investors Need to Know
-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
Going Into Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?
-
What’s the Difference Between the CPI and PCE Indexes?
-
5 Stocks to Buy That We Still Like After They’ve Run Up
-
Markets Brief: Stocks Are Starting to Look Cheap Again
-
AbbVie Earnings: Next-Generation Immunology Drugs Help Offset Humira Biosimilar Pressure
-
Exxon Earnings: Ignore Earnings Shortfall as Long-Term Growth and Improvement on Track
-
American Airlines Earnings: We See Costs Overshadowing Market Share This Year
-
Snap Earnings: Advertising Growth and Snapchat+ Drive Monetization
-
STMicro Earnings: We Still See an Attractive Margin of Safety Despite a Poor First-Half Forecast
-
Alphabet Shares Surge on Strong Earnings, Dividend Surprise
-
Microsoft Earnings: Firm Beats Forecasts on Strong AI and Cloud Demand
-
PG&E Earnings: Near-Term Regulatory Certainty Supports Industry-Leading Earnings Growth